Aethlon Medical, Inc. reported financial results for its fiscal third quarter ended December 31, 2025, including a net loss of $2.02 million and a cash balance of $7.0 million, while providing updates on clinical trial progress and operational cost efficiencies.
Key takeaways
Reported a net loss of $2.02 million for the quarter ended December 31, 2025, compared to a net loss of $1.75 million in the prior year period.
Had a cash balance of approximately $7.0 million as of December 31, 2025.
Operating expenses for the quarter increased 13.6% to $2.06 million, primarily due to higher payroll costs.
Operating expenses for the nine months ended December 31, 2025 decreased 26.9% to $5.36 million compared to the same period in 2024.
Cohort 2 of the Australian oncology trial is actively progressing, building on Cohort 1 results.
Maintained Nasdaq listing compliance with all prior compliance matters resolved.